Autres langues Waters Corporation

Actions

WAT

US9418481035

Equipement et technologie médicale avancés

Marché Fermé - NYSE 22:03:35 07/10/2026			Varia. 5j.	Varia. 1 janv.
435,99 ^USD	-0,10%		-0,77%	+14,79%

07/10	Waters Corporation : Evercore ISI n'est plus à la vente	ZM
06/10	Waters Corporation : Barclays persiste à l'achat	ZM

Autres langues

05/10	CellCarta and Waters Corporation Establish Strategic Partnership to Advance Companion Diagnostics Development
01/10	Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call
16/09	Everlywell Announces Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. to Patients
14/09	Waters Corporation Announces Global Commercial Launch of BD FACSDiscover A7 Cell Analyzer
14/09	Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer
14/09	Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer
11/09	Waters Corporation to Present at the J.P. Morgan U.S. All Stars Conference
27/08	Waters Shares Rise After Piper Sandler Upgrade
27/08	Analyst recommendations: Block, Celsius, Crowdstrike, Gitlab, Nvidia…
26/08	Waters Corporation to Present at the Wells Fargo Healthcare Conference
24/08	Qiagen macht Jonathan Pratt zum neuen Konzernchef
24/08	Waters' Q4 Guide Conservative, 2027 Growth Could Reach High Single Digits, RBC Says
21/08	Waters Corporation Announces Executive Changes
11/08	Tranche Update on Waters Corporation's Equity Buyback Plan announced on January 23, 2019.
06/08	Becton Dickinson raises lower end of annual profit forecast on drug delivery devices strength
04/08	Waters Corporation Provides Earnings Guidance for the Third Quarter Ending October 3, 2026 and Full Fiscal Year Ending December 31, 2026
04/08	Waters Corporation Reports Earnings Results for the Second Quarter and Six Months Ended July 04, 2026
04/08	Waters lifts annual forecasts on strong lab-equipment and diagnostics demand
04/08	Waters Fiscal Q2 Adjusted Earnings, Net Revenue Rise: Issues Q3 Guidance
04/08	(WAT) Waters Expects 2026 Revenue Range $6.42B - $6.48B, vs. FactSet Est of $6.44B
04/08	(WAT) Waters Expects Full Year 2026 Adjusted EPS Range $14.45 - $14.65, vs. FactSet Est of $14.52
04/08	(WAT) Waters Corporation Expects Q3 Adjusted EPS Range $3.95 - $4.05
04/08	Earnings Flash (WAT) Waters Corporation Reports Q2 Revenue $1.65B, vs. FactSet Est of $1.62B
04/08	Earnings Flash (WAT) Waters Corporation Posts Q2 Adjusted EPS $3.05 per Share, vs. FactSet Est of $3.01
04/08	(WAT) Waters Corporation Expects Q3 Revenue Range $1.75B - $1.76B